The following is the summary of “p-Cresyl sulfate predicts clinical outcomes in sustained peritoneal dialysis: a 5-year follow-up cohort study and meta-analysis” published in the October 2022 issue of Renal failure by Chen, et al.
Prognosis in uremia patients and the role of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) are still debatable. To better understand the correlation between PCS or IS levels and clinical outcomes, researchers conducted a prospective study of peritoneal dialysis (PD). The purpose of this prospective cohort study was to examine the correlation between serum PCS and IS and clinical outcomes in PD patients. Their team used a correlation analysis to determine the causes and effects between PCS and IS. Objectively assessing the predictive impact of PCS and IS throughout Chronic kidney disease (CKD) stages was the goal of this meta-analysis.
Researchers enrolled 127 patients in a row and followed them for an average of 51.3 months. Serum total PCS was associated with an increased risk of a cardiovascular event (HR: 1.08, 95% CI=1.04 to 1.13, P<0.001), PD-associated peritonitis (HR: 1.04, 95% CI=1.02 to 1.08, P=0.001), and PD failure event (HR: 1.05, 95% CI=1.02 to 1.07, P<0.001) in a multivariate Cox regression analysis. In addition, patients with total PCS levels greater than 18.99 mg/L, determined as the optimal cutoff value from the ROC curve, had a poorer prognosis.
Its benefit in preventing cardiovascular events in PD was verified by a meta-analysis. Increased PD failure, cardiovascular events, and PD-related peritonitis were all associated with greater blood total PCS concentrations. It can potentially serve as a novel marker for predicting poor clinical outcomes in PD.
Source: tandfonline.com/doi/full/10.1080/0886022X.2022.2136528